Ikarian Capital’s NextCure NXTC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.51M Hold
238,303
0.2% 86
2025
Q4
$3.38M Buy
+238,303
New +$2.47M 0.26% 77
2022
Q3
Sell
-5,953
Closed -$336K 147
2022
Q2
$336K Sell
5,953
-5,802
-49% -$303K 0.06% 108
2022
Q1
$686K Buy
11,755
+584
+5% +$36.5K 0.09% 114
2021
Q4
$804K Sell
11,171
-31,259
-74% -$2.62M 0.12% 107
2021
Q3
$3.43M Sell
42,430
-643
-1% -$56.4K 0.24% 92
2021
Q2
$4.15M Buy
43,073
+5,244
+14% +$537K 0.34% 77
2021
Q1
$4.54M Buy
37,829
+21,162
+127% +$3.06M 0.15% 128
2020
Q4
$2.18M Hold
16,667
0.1% 152
2020
Q3
$1.76M Buy
+16,667
New +$2.05M 0.13% 115

Other funds holding NXTC

Ikarian Capital's NXTC Position: Q1 2026 in Review

Ikarian Capital held its NextCure (NXTC) position steady in Q1 2026 at 238,303 shares worth $2.51M. The position accounts for 0.2% of the portfolio, ranked #86.

Ikarian Capital first reported a position in NXTC in Q3 2020 and has held it in 10 quarters since. The position peaked at $4.54M in Q1 2021. 26 funds tracked by Wall St. Rank hold NXTC as of Q1 2026.

  • Ikarian Capital held 238,303 shares of NextCure worth $2.51M as of Q1 2026.
  • Ikarian Capital left its NextCure share count unchanged in Q1 2026.
  • NextCure made up 0.2% of Ikarian Capital's portfolio in Q1 2026, its #86 holding.
  • Ikarian Capital first reported a position in NextCure in Q3 2020 and has held it in 10 quarters since.
  • Ikarian Capital's NextCure position peaked at $4.54M in Q1 2021.
  • 26 funds tracked by Wall St. Rank held NextCure as of Q1 2026.

Based on Ikarian Capital's 13F filing for Q1 2026, filed 15 May 2026.